期刊文献+

妇科尿毒症者血液中分子代谢物的清除及作用机制探讨 被引量:1

Investigation of the mechanisms of clearances of middle molecular metabolites from blood of gynecological patients with uremia
下载PDF
导出
摘要 目的为了探讨妇科尿毒症患者血液中分子代谢物清除方法及分子病理学机制。方法回顾性总结我院收治妇科尿毒症患者44例资料,按照血液中中分子代谢物清除方法不同分为两组:单纯透析疗法的22例资料为对照组,在对照组治疗基础上加用血液透析串联血液灌流治疗的22例为观察组,术后按照文章疗效标准进行统计,最后讨论分子病理学机制。结果观察组患者治疗后血液中中分子大小的代谢废物平均水平为(3182.4±344.5)U/L,明显低于治疗前的平均值(4108.3±530.5)U/L(P<0.05),观察组患者治疗后临床症状改善情况(改善率86.4%)明显优于对照组统计结果(P<0.05)。结论妇科尿毒症患者及时通过血液透析串联血液灌流方法进行清除中分子代谢物,对于维持机体生理功能的平衡具有重要的临床意义。 Objective To investigate the clearance methods and molecular pathological mechanisms of middle molecular metabolites from blood of gynecological patients with uremia.Methods44 uremic cases were analyzed retrospectively from our hospital.According to clearance methods for middle molecular metabolites from blood,44 patients were divided into two groups:control group(patients were given only dialysis therapy,n = 22) and observation group(patients were treated with hemodialysis combined with hemoperfusion,n = 22).Curative effects after operation were collected,and the mechanisms of molecular pathology were discussed.Results Average level of middle molecular metabolites in blood of patients in the observation group after treatment was(3 182.4 ± 344.5) U/L,which was significantly lower than the average value before treatment(4 108.3 ± 530.5) U/L(P〈0.05).The rate of improvement of the clinical symptoms in patients of the observation group(86.4%) was better than that of the control group(P〈0.05)significantly after treatment.Conclusion To clean the middle molecular metabolites from blood of gynecological patients with uremia by adopting hemoperfusion combined with hemodialysis in series is significantly important and useful for the maintenance of physiological functions.
出处 《分子诊断与治疗杂志》 2014年第5期334-336,共3页 Journal of Molecular Diagnostics and Therapy
关键词 尿毒症 血液灌流 透析治疗 Uremia Hemoperfusion Hemodialysis
  • 相关文献

参考文献15

  • 1Chen T S,Liou S Y,Chang Y L,et al.The clearance of unidentified uremic solutes (with molecular weight under 5 kDa) plays an important role in hemodialyzer selection[J].International Urology and Nephrology,2010,42(2):465-470.
  • 2Huang W H,Hung C C,Yang C W,et al.High correlation between clearance of renal protein-bound uremic toxins (indoxyl sulfate and p-cresyl sulfate) and renal water-soluble toxins in peritoneal dialysis patients[J].Therapeutic Apheresis and Dialysis,2012,16(4):361-367.
  • 3Thomas G,Jaber B L.Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease:a review of the evidence[J].Seminars in Dialysis,2009,22(6):610-614.
  • 4Gerritsen K G,Abrahams A C,Peters H P,et al.Effect of GFR on plasma N-terminal connective tissue growth factor (CTGF) concentrations[J].American Journal of Kidney Diseases,2012,59(5):619-627.
  • 5Shoji T,Hatsuda S,Tsuchikura S,et al.Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia[J].Atherosclerosis,2009,207(2):579-584.
  • 6Shoji T,Hatsuda S,Tsuchikura,et al.Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia[J].Atherosclerosis,2009,207(2):579-584.
  • 7Twardowski Z J.Treatment time and ultrafiltration rate are more important in dialysis prescription than small molecule clearance[J].Blood Purification,2007,25 (1):90-98.
  • 8Ayvaz S,Aksu B,Kanter M,et al.Preventive effects of hyperbaric oxygen treatment on glycerol-induced myoglobinuric acute renal failure in rats[J].Journal of Molecular Histology,2012,43(2):161-170.
  • 9Boelaert J,Lynen F,Glorieux G,et al.A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients[J].Analytical and Bioanalytical Chemistry,2013,405(6):1937-1947.
  • 10Itoh Y,Ezawa A,Kikuchi K,et al.Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production[J].Analytical and Bioanalytical Chemistry,2012,403 (7):1841-1850.

同被引文献11

引证文献1

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部